Financial reports
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
2 Mar 20
10-Q
2019 Q3
Quarterly report
6 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
1 Mar 19
10-Q
2018 Q3
Quarterly report
6 Nov 18
10-Q
2018 Q2
Quarterly report
7 Aug 18
10-Q
2018 Q1
Quarterly report
4 May 18
Current reports
8-K
Entry into a Material Definitive Agreement
13 Oct 20
8-K
Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics
31 Aug 20
8-K
Akcea Reports Financial Results and Highlights for Second Quarter 2020
4 Aug 20
8-K
Akcea Announces Appointment of New Chief Medical Officer
9 Jul 20
8-K
Departure of Directors or Certain Officers
19 Jun 20
8-K
Akcea Announces Appointment of New Chief Financial Officer
18 May 20
8-K
Akcea Reports Financial Results and Highlights for First Quarter 2020
5 May 20
8-K
Departure of Directors or Certain Officers
29 Apr 20
8-K
Entry into a Material Definitive Agreement
9 Apr 20
8-K
Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
24 Mar 20
Registration and prospectus
15-12B
Securities registration termination
23 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
POSASR
Automatic shelf registration (post-effective amendment)
13 Oct 20
SC 13E3/A
Going private transaction (amended)
13 Oct 20
SC 14D9/A
Tender offer solicitation (amended)
13 Oct 20
25-NSE
Exchange delisting
13 Oct 20
Proxies
DEFA14C
Additional information
4 Mar 20
DEF 14C
Information statement
4 Mar 20
DEFA14C
Additional information
29 Apr 19
DEF 14C
Information statement
29 Apr 19
DEF 14C
Information statement
28 Nov 18
DEF 14C
Information statement
20 Apr 18
DEFA14A
Additional proxy soliciting materials
28 Mar 18
DEF 14A
Definitive proxy
26 Mar 18
DEFA14A
Additional proxy soliciting materials
26 Mar 18
DEFA14A
Additional proxy soliciting materials
16 Mar 18
Other
CORRESP
Correspondence with SEC
24 Sep 20
UPLOAD
Letter from SEC
24 Sep 20
UPLOAD
Letter from SEC
23 Sep 20
CT ORDER
Confidential treatment order
21 Sep 20
CT ORDER
Confidential treatment order
21 Sep 20
CT ORDER
Confidential treatment order
5 Jun 19
CT ORDER
Confidential treatment order
18 Dec 18
CT ORDER
Confidential treatment order
13 Jul 17
EFFECT
Notice of effectiveness
13 Jul 17
CORRESP
Correspondence with SEC
11 Jul 17
Ownership